Early diagnosis and intervention for transthyretin amyloidosis (ATTR) is critical, yet does not occur, typically as a consequence of the rarity and heterogeneity of the disease and limited awareness on the part of clinicians. Therapeutic options are limited, but there are new and emerging agents and emerging indications with which clinicians may not be familiar. Access to specialized care centers is limited for many patients, leading to suboptimal management and disease monitoring. This education fills a significant need for healthcare team education to ensure all patients benefit from best-practices in recognizing, diagnosing, and managing amyloidosis.